Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update
May 08, 2024 16:16 ET | Catalyst Pharmaceuticals, Inc.
Achieved Total Q1 2024 Revenues of $98.5 Million, a 15.4% YoY Increase, Underscored by Exceptional Execution and Continued Demand for Commercial Products FIRDAPSE® Q1 2024 Net Product Revenues of...
Global Market for Duchenne Muscular Dystrophy Drugs
Global Duchenne Muscular Dystrophy Drugs Business Report 2023: Market to Reach $18.1 Billion by 2030, Growing at a Staggering CAGR of 42.5%
January 26, 2023 11:03 ET | Research and Markets
Dublin, Jan. 26, 2023 (GLOBE NEWSWIRE) -- The "Duchenne Muscular Dystrophy Drugs - Global Strategic Business Report" report has been added to's offering.Global Duchenne...
Vantage Market Research.png
Global Dystrophin Market to Reach USD 30.22 Billion by 2028 - Heavy Research & Development to Boost the Market Demand – Vantage Market Research
February 16, 2022 05:35 ET | Vantage Market Research
WASHINGTON, Feb. 16, 2022 (GLOBE NEWSWIRE) -- The Global Dystrophin Market size is expected to reach USD 30.22 Billion by 2028, exhibiting a Compound Annual Growth Rate (CAGR) of 45.9% during the...
Duchenne Muscular Dystrophy Worldwide Outlook to 2030: Upcoming Strategies Include Gene Therapy and Cell Therapy
November 03, 2021 05:23 ET | Research and Markets
Dublin, Nov. 03, 2021 (GLOBE NEWSWIRE) -- The "Duchenne Muscular Dystrophy - Market Insight, Epidemiology and Market Forecast -2030" report has been added to's offering. Key...
RND logo.PNG
Dystrophin Market To Reach USD 13.02 Billion By 2026 | Reports And Data
March 05, 2019 07:46 ET | Reports And Data
High disease prevalence across the globe coupled with ongoing research & development is expected to stimulate market growth Market Size – USD 597.3 million in 2018, Market Growth - CAGR of...